Did You Know...
...that Thomas Edison's patent application on his phonograph was approved by the Patent Office in just seven weeks? In contrast, it took Gordon Gould, the inventor of the laser, 30 years to obtain his patent -- finally awarded in 1988!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178542 | Methods and compositions for treating pain The present application relates to compounds and methods for treating pain, incontinence and other conditions. ... | 05/15/2012 |
| 7671061 | Methods and compositions for treating pain The present application relates to compounds and methods for treating pain, incontinence and other conditions. ... | 03/02/2010 |
| 7423041 | A1 adenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 09/09/2008 |
| 7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs t... | 08/05/2008 |
| 7312223 | Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. ... | 12/25/2007 |
| 7279483 | Famciclovir monohydrate Famciclovir monohydrate and its pharmaceutical use. ... | 10/09/2007 |
| 7271271 | Imidazolo-related compounds, compositions and methods for their use Compounds are provided having the formula: wherein variables R0, R1, R2, R3, R4, Q, L and subscript n are as described herein. The subject compounds are usef... | 09/18/2007 |
| 7247639 | A1 adenosine receptor antagonists The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceut... | 07/24/2007 |
| 7229473 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-bas... | 06/12/2007 |
| 7230000 | Methods and compositions utilizing quinazolinones Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity ... | 06/12/2007 |
| 7223286 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-bas... | 05/29/2007 |
| 7217286 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-bas... | 05/15/2007 |
| 7202252 | Aadenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 04/10/2007 |
| 7098217 | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands 3,7-Dihydro-purine-2,6-dione derivatives of Formula (I) are provided wherein R1, R2, R3 and R4 are herein defined for use as CRF receptor ligands in the treatment of di... | 08/29/2006 |
| 7074801 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof The present invention discloses compounds and compositions of formula (I): having inhibitory activity on activation of STAT6, wherein X represents quinoline, isoquinoline, quinazoline or imidazopyridine; Y repres... | 07/11/2006 |
| 7074923 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to sy... | 07/11/2006 |
| 7053096 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. ... | 05/30/2006 |
| 6946465 | Immunosuppressive effects of pteridine derivatives Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, b... | 09/20/2005 |
| 6878715 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 04/12/2005 |
| 6869974 | Pharmaceutical compounds Compounds or their salts having general formulas (I) and (II): wherein s is an integer equal to 1 or 2, A is the radical of a drug that satisfies certain pharmacological tests, C and C1 are bivalent radicals, and precursors of the radicals B and B1 | 03/22/2005 |
| 6780865 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. The disclosed compounds have a structure of formula I: ... | 08/24/2004 |
| 6734187 | Purine derivatives and medicaments comprising the same as active ingredient Purine derivatives represented by the following formula and salts thereof: wherein R1 represents a C1-C4 alkyl group or difluoromethyl group; R2 represents tetrahydrofuranyl gr... | 05/11/2004 |
| 6649600 | Adenosine receptor antagonists and methods of making and using the same The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of n... | 11/18/2003 |
| 6638938 | Method for preventing tissue injury from hypoxia There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an i... | 10/28/2003 |
| 6608069 | Phenyl xanthine derivatives The present invention relates to novel compounds of formula (I): ##STR1## wherein Z represents a 5 or 6 membered cycloalkyl, aryl, substituted cycloalkyl, or substituted aryl, said cycloalkyl, aryl, substituted cycloalkyl or substituted aryl optionally co... | 08/19/2003 |
| 6605600 | Adenosine receptor antagonists and methods of making and using the same The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of nu... | 08/12/2003 |
| 6558660 | Method for regulating IL-10 with IL-9, and applications thereof The invention involves the recognition of IL-9 as a molecule involved in induction of IL-10. Administration of IL-9 leads to protection against conditions where IL-10 production is warranted, such as infections by Gram negative bacteria. Examples of such ... | 05/06/2003 |
| 6489332 | A1 adenosine receptor antagonists A compound useful as an A1 adenosine receptor antagonist has the formula: ##STR1## wherein R1 is selected from the group consisting of C1 -C8 alkyl; R2 is of the formula: ##STR2## wherein is an integ... | 12/03/2002 |
| 6423719 | Method for treating benign prostate hyperplasia A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: ##STR1## is described herein. Administration of dyphylline in a sustained release ... | 07/23/2002 |
| 6350752 | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring gene... | 02/26/2002 |
| 6319894 | Complexes and combinations of fetuin with therapeutic agents There is disclosed a complex and a combination of the glycosylated polypeptide fetuin and a therapeutically active small molecule compound having a net positive charge at physiological pH. The presence of fetuin as a drug complex or in combination with th... | 11/20/2001 |
| 6313131 | Method of kidney treatment A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: ##STR1## is described herein. Administration of dyphylline in a sustained release ... | 11/06/2001 |
| 6187780 | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity Asymmetrically substituted xanthine derivatives having adenosine A1 antagonistic activity. These are useful as pharmaceuticals. Exemplary are: (a) 3-(2-(2-acetyloxyethyl)sulphonylethyl)-8-(1-noradamantyl)-1-n-propyl-xanth ine; (b) 3-(2-(hyd... | 02/13/2001 |
| 6103730 | Amine substituted compounds Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula: CORE MOIETY--(R)j In these compounds, j is an integer from one to three; the core moiet... | 08/15/2000 |
| 6100271 | Therapeutic compounds containing xanthinyl Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R)j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R m... | 08/08/2000 |
| 6043250 | Methods for using therapeutic compounds containing xanthinyl Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R)j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R m... | 03/28/2000 |
| 6025361 | Trisubstituted thioxanthines Disclosed are compounds of formula (I), wherein R1, R3 and R8 are independently alkyl, aryl or aralkyl, and R2 is selected from the group consisting of S and O, R6 is selected from the group consistin... | 02/15/2000 |
| 5965555 | Xanthine compounds having terminally animated alkynol side chains Compounds of the formula I, ##STR1## in which one of the radicals R1 and R3 is an alkynol residue of the formula Ia or Ib ##STR2## are suitable for producing pharmaceuticals having a neuroprotective effect.... | 10/12/1999 |
| 5958933 | Neurologically active compounds and compounds with multiple activities A method for treating a mammal having a damaged central nervous system, as the result of trauma or disease, for reestablishing previously destroyed neurological functions in a traumatized or diseased mammal, or for controlling spasticity and for providing... | 09/28/1999 |
| 5929081 | Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF and VEGF There is disclosed a method for: (1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of ca... | 07/27/1999 |
